St Jude Medical, Inc has launched the Ellipse implantable cardioverter defibrillator (ICD) in India. Some of the first implants recently took place at the Fortis Escorts Hospital in New Delhi by Dr Aparna Jaswal, Senior Consultant Cardiologist. ICDs are advanced implantable cardiac devices that treat potentially lethal, abnormally fast heart rhythms (ventricular tachycardia or ventricular fibrillation) that often lead to sudden cardiac death (SCD).
The Ellipse ICD claims advanced features and a physician-inspired shape that is unlike any currently available ICDs. “We are pleased to have the new Ellipse ICD at Fortis Escorts Hospital, as it provides a balance of energy, longevity, thinness and a smaller device footprint, which collectively makes a tremendous difference for my patients,” said Dr Jaswal.
Within its unique design, the device contains new features like expanded ShockGuard technology for protection against inappropriate and unnecessary therapy, high energy delivery, CorVue congestion monitoring, and enhanced ST Monitoring to offer greater insight into ischemia-related ventricular arrhythmias.
The Ellipse ICD adds SecureSense RV lead noise discrimination, a new algorithm that offers a strong set of lead monitoring capabilities which helps physicians proactively lower the risk of lead-related complications.
“The launch of the physician-inspired Ellipse ICD represents the company’s ongoing efforts to incorporate physician feedback into our products,” said Kaustav Banerjee, India Country Manager for St. Jude Medical. “The refinements to the shape of the Ellipse device, that make it easier to implant and more comfortable for the patient over time, really demonstrate the value of this approach.”
EH News Bureau